PART I: FINANCIAL INFORMATION [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited condensed consolidated financial statements for Q1 2024, highlighting significant growth in revenues and net income [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheet as of March 31, 2024, reflects an increase in total assets to **$7.14 billion** and total stockholders' equity to **$5.39 billion** Key Balance Sheet Items (in thousands) | Account | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | **Current Assets** | | | | Cash and cash equivalents | $3,346,204 | $3,213,376 | | Total current assets | $4,849,091 | $4,645,402 | | **Total Assets** | **$7,135,605** | **$6,782,107** | | **Current Liabilities** | | | | Total current liabilities | $1,396,453 | $1,240,379 | | **Total Liabilities** | **$1,741,334** | **$1,592,270** | | **Total Stockholders' Equity** | **$5,394,271** | **$5,189,837** | [Condensed Consolidated Statements of Operations](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q1 2024 statements show total revenues increased by **9%** to **$880.9 million**, with net income surging to **$169.5 million** due to an unrealized investment gain Q1 Statement of Operations Highlights (in thousands, except per share data) | Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Total revenues | $880,889 | $808,673 | | Income from operations | $91,898 | $24,770 | | Unrealized gain (loss) on long term investments | $99,947 | $(5,318) | | Net income | $169,548 | $21,703 | | Diluted net income per share | $0.75 | $0.10 | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Q1 2024 saw net cash provided by operating activities reach **$218.8 million**, a significant improvement, with total cash increasing to **$3.35 billion** Q1 Cash Flow Summary (in thousands) | Cash Flow Activity | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Net cash provided by (used in) operating activities | $218,811 | $(105,603) | | Net cash used in investing activities | $(73,112) | $(28,559) | | Net cash (used in) provided by financing activities | $(12,413) | $4,009 | | **Net increase (decrease) in cash** | **$132,610** | **$(130,352)** | [Notes to Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Detailed notes cover accounting policies, revenue disaggregation, and key business events including acquisitions, collaborations, and contingent liabilities Disaggregated Revenue (in thousands) | Product/Royalty | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | JAKAFI revenues, net | $571,839 | $579,969 | | OPZELURA revenues, net | $85,724 | $56,552 | | Total product revenues, net | $729,923 | $693,237 | | Total product royalty revenues | $125,966 | $115,436 | | Milestone and contract revenues | $25,000 | $— | | **Total revenues** | **$880,889** | **$808,673** | - In February 2024, Incyte acquired exclusive global rights to tafasitamab (MONJUVI/MINJUVI) from MorphoSys for a **$25.0 million** payment, terminating their prior collaboration agreement[44](index=44&type=chunk) - In March 2024, Incyte entered a collaboration with China Medical System Holdings Limited (CMSHL) for povorcitinib, recognizing a **$25.0 million** upfront payment as milestone and contract revenue[72](index=72&type=chunk) - The company has accrued approximately **$73.7 million** as of March 31, 2024, for potential incremental Medicaid rebates if OPZELURA is deemed a "line extension" of JAKAFI by CMS[99](index=99&type=chunk) - Subsequent to the quarter end, in April 2024, Incyte entered into an agreement to acquire Escient Pharmaceuticals for **$750.0 million** plus Escient's net cash[101](index=101&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=23&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q1 2024 financial performance, highlighting a **9%** revenue increase to **$880.9 million**, driven by product sales and pipeline advancements, alongside a strong liquidity position [Overview](index=28&type=section&id=Overview) Incyte is a global biopharmaceutical company focused on Hematology/Oncology and Inflammation & Autoimmunity, advancing a broad clinical pipeline and strategic acquisitions - The company's two primary therapeutic areas are Hematology/Oncology (including MPNs, GVHD, solid tumors) and Inflammation and Autoimmunity (IAI), which includes its Dermatology franchise[116](index=116&type=chunk) - In February 2024, Incyte acquired exclusive global rights for tafasitamab (MONJUVI/MINJUVI) from MorphoSys, terminating their previous collaboration[139](index=139&type=chunk) - A Biologics License Application (BLA) for axatilimab for chronic GVHD was submitted and accepted for Priority Review by the FDA in February 2024[162](index=162&type=chunk) - In April 2024, Incyte entered an agreement to acquire Escient Pharmaceuticals, a clinical-stage company focused on immune and neuro-immune disorders, for **$750 million** plus net cash[238](index=238&type=chunk)[239](index=239&type=chunk) [Results of Operations](index=46&type=section&id=Results%20of%20Operations) Q1 2024 total revenues increased to **$880.9 million**, driven by OPZELURA growth and a milestone payment, while JAKAFI revenues slightly declined and net income benefited from an unrealized gain Q1 2024 vs Q1 2023 Revenue Breakdown (in millions) | Revenue Source | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | JAKAFI revenues, net | $571.8 | $580.0 | | OPZELURA revenues, net | $85.7 | $56.6 | | MINJUVI/MONJUVI revenues, net | $23.9 | $6.5 | | Total product revenues, net | $729.9 | $693.3 | | Total product royalty revenues | $126.0 | $115.4 | | Milestone and contract revenues | $25.0 | $— | | **Total revenues** | **$880.9** | **$808.7** | - The decrease in JAKAFI net product revenues was primarily driven by a decrease in channel inventory, which offset a price increase[256](index=256&type=chunk) - The increase in MINJUVI/MONJUVI net product revenues was driven by the asset acquisition completed in February 2024, which gave Incyte exclusive global rights[256](index=256&type=chunk) Q1 2024 vs Q1 2023 Operating Expenses (in millions) | Expense Category | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Cost of product revenues | $61.0 | $56.8 | | Research and development | $429.3 | $406.6 | | Selling, general and administrative | $300.3 | $315.6 | [Liquidity and Capital Resources](index=50&type=section&id=Liquidity%20and%20Capital%20Resources) As of March 31, 2024, Incyte maintained a strong liquidity position with **$3.9 billion** in cash and marketable securities, supported by **$218.8 million** in Q1 operating cash flow - As of March 31, 2024, the company had **$3.9 billion** in available cash, cash equivalents, and marketable securities[275](index=275&type=chunk) - Net cash provided by operating activities for Q1 2024 was **$218.8 million**, compared to net cash used of **$105.6 million** in Q1 2023, primarily due to changes in working capital[276](index=276&type=chunk) - The company has a **$500.0 million** senior unsecured revolving credit facility, which was undrawn as of March 31, 2024[279](index=279&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=51&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company's market risk primarily stems from its **$504.5 million** investment portfolio in U.S. government debt, with a **10%** interest rate increase deemed immaterial - The company's investments in marketable securities, totaling **$504.5 million** as of March 31, 2024, are primarily composed of U.S. government debt securities[283](index=283&type=chunk) - The company is exposed to interest rate risk, but management has determined that a hypothetical **10%** increase in market interest rates would not have a material impact on the portfolio's fair value[283](index=283&type=chunk) [Controls and Procedures](index=52&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, 2024, with no material changes to internal control over financial reporting during Q1 - The Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures were effective as of March 31, 2024[286](index=286&type=chunk) - There were no material changes in internal control over financial reporting during the first quarter of 2024[287](index=287&type=chunk) PART II: OTHER INFORMATION [Risk Factors](index=52&type=section&id=Item%201A.%20Risk%20Factors) This section outlines significant risks including heavy dependence on JAKAFI, competition, pricing pressures, and inherent uncertainties in drug development and manufacturing - The company depends heavily on its lead product, JAKAFI, and any decrease in its revenues could materially harm the business[289](index=289&type=chunk) - The business faces significant risk from pricing and reimbursement pressures, including government health care reform measures like the Inflation Reduction Act, which could limit drug prices and profitability[294](index=294&type=chunk)[338](index=338&type=chunk) - Competition is a major risk, with potential for decreased revenue from existing therapies, new products from competitors, and generic versions of Incyte's products, including a noted ANDA filing for a generic version of JAKAFI[320](index=320&type=chunk)[322](index=322&type=chunk) - The company relies on third parties for manufacturing its key products, which creates risks related to supply constraints, quality control, and regulatory compliance[354](index=354&type=chunk) - There are significant risks associated with the discovery and development of new drugs, including the possibility of clinical trial failures, inability to obtain regulatory approval, and the high costs involved[328](index=328&type=chunk)[331](index=331&type=chunk) [Other Information](index=80&type=section&id=Item%205.%20Other%20Information) This section discloses that three company officers adopted prearranged trading plans under Rule 10b5-1(c) during Q1 2024 - Steven Stein, EVP and Chief Medical Officer, adopted a trading plan on February 20, 2024, for the sale of up to **20,147 shares**[410](index=410&type=chunk) - Barry Flannelly, EVP and General Manager, North America, adopted a trading plan on February 20, 2024, for the sale of up to **52,931 shares**[411](index=411&type=chunk) - Thomas Tray, VP, Chief Accounting Officer, adopted a trading plan on March 7, 2024, for the sale of up to **1,093 shares**[411](index=411&type=chunk) [Exhibits](index=81&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including the 2024 Inducement Stock Incentive Plan and Sarbanes-Oxley Act certifications - The filing includes documents for the company's 2024 Inducement Stock Incentive Plan (Exhibits 10.1-10.4)[414](index=414&type=chunk) - Certifications by the CEO and CFO under Rules 13a-14(a) and Section 906 of the Sarbanes-Oxley Act are included as Exhibits 31.1, 31.2, 32.1, and 32.2[414](index=414&type=chunk)

Incyte Corporation (INCY) reported first-quarter 2024 adjusted earnings of 64 cents per share, which missed the Zacks Consensus Estimate of 88 cents. The company had recorded earnings of 37 cents per share in the year-ago quarter.Total revenues in the reported quarter were $881 million, which grew 9% year over year, driven by the sustained performance of its lead drug, Jakafi (ruxolitinib), and increased sales of Opzelura (ruxolitinib) cream on strong launch and demand. The top line, however, missed the Zac ...

Financial Data and Key Metrics Changes - Total revenues for the first quarter reached $881 million, reflecting a 9% increase compared to the same period last year [5][70] - Total product revenues amounted to $730 million, driven by demand growth for Jakafi and Opzelura, along with increased revenue from Monjuvi following its acquisition [5][70] - Jakafi net product revenues were $572 million, with a 5% year-over-year increase in total patients, primarily from PV and GVHD [91][70] - Opzelura net product revenues were $86 million, representing a 52% increase year-over-year, with a 41% growth in total prescriptions [85][121] Business Line Data and Key Metrics Changes - Jakafi experienced the highest quarter paid demand since its launch, with a notable increase in patient numbers [6][70] - Opzelura's growth was impacted by a cyber-attack on Change Healthcare, which caused a temporary decline in claims processing [26][121] - The oncology pipeline includes a potentially best-in-class CDK2 inhibitor, with data expected later this year [4][70] Market Data and Key Metrics Changes - The AD market, including Opzelura, grew 23%, while Opzelura outpaced this growth with a 41% increase in prescriptions [85][121] - The company maintains a stable market share in myelofibrosis, with no significant impact from competitors [71][131] Company Strategy and Development Direction - The company announced an agreement to acquire Escient Pharmaceuticals for $750 million, enhancing its pipeline with two first-in-class medicines [1][7] - The strategic focus includes delivering 10 high-impact launches by 2030, with several programs already post-proof-of-concept [86][70] - The company aims to leverage its existing capabilities to realize synergies from the Escient acquisition [7][78] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth of Jakafi, anticipating a full-year revenue guidance of $2.69 billion to $2.75 billion [84][98] - The company is optimistic about the potential of its pipeline, particularly in addressing unmet medical needs in inflammatory diseases and oncology [64][117] - Management noted that the competitive landscape for Jakafi remains stable, with no significant changes in patient persistence or market share [131][138] Other Important Information - The company has a strong balance sheet with $3.9 billion in cash and no debt, allowing for potential future investments [78][150] - R&D expenses for the first quarter were $429 million, a 6% increase year-over-year, while SG&A expenses decreased by 5% [92][120] Q&A Session Summary Question: Can you provide insights on Opzelura's growth dynamics for the rest of the year? - Management indicated that they are monitoring prescription trends and expect continued growth despite the impact of the cyber-attack [26][121] Question: What are the growth dynamics for Jakafi given the IRA and out-of-pocket expenses? - Management noted that reduced out-of-pocket expenses for patients starting in 2025 would benefit Jakafi's growth, particularly in PV and GVHD [14][98] Question: How does the company view the competitive landscape for Jakafi? - Management stated that there has been no significant impact on Jakafi's market share or patient persistence from competitors [131][138] Question: What is the company's strategy regarding capital redeployment? - Management confirmed that they are exploring various opportunities, including potential share buybacks, while maintaining a strong balance sheet [150][151]

For the quarter ended March 2024, Incyte (INCY) reported revenue of $880.89 million, up 8.9% over the same period last year. EPS came in at $0.64, compared to $0.37 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $935.85 million, representing a surprise of -5.87%. The company delivered an EPS surprise of -27.27%, with the consensus EPS estimate being $0.88.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they ...

Financial Performance - Total net revenues for Q1 2024 were $881 million, a 9% increase year-over-year compared to $809 million in Q1 2023[79] - Jakafi net sales in Q1 2024 were $572 million, a 1% decrease year-over-year compared to $580 million in Q1 2023[79] - Opzelura net sales in Q1 2024 were $86 million, a 52% increase year-over-year compared to $57 million in Q1 2023[79] - Royalty revenues in Q1 2024 were $126 million, a 9% increase year-over-year compared to $115 million in Q1 2023[79] - The company is reiterating its FY'24 Jakafi net sales guidance of $269 to $275 billion[23] Pipeline Development - Axatilimab is under priority review for 3L+ cGVHD with potential approval in 2H 2024[35, 51] - A Phase 3 study of BETi + ruxolitinib is expected to be initiated[20, 91] - A Phase 3 trial of povorcitinib in prurigo nodularis is expected to be initiated in 2024[20, 85, 91] - The company anticipates several potential launches starting in 2029[13] Strategic Initiatives - Incyte is acquiring Escient Pharmaceuticals in an all-cash transaction for $750 million, expected to close by Q3 2024[72, 126]

Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs Conference Call and Webcast Scheduled Today at 8:00 a.m. ET WILMINGTON, Del. – April 30, 2024 – Incyte (Nasdaq:INCY) today reports 2024 first quarter financial results, and provides a status update on the Company's clinical development portfolio. Exhibit 99.1 FOR IMMEDIATE RELEASE "In the first quarter of 2024, total revenues grew 9% year-over-year driven by patient demand growth in the U.S. for Opzelura® (ruxo ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Incyte (INCY) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on April 30, 2024, might help the stock move higher if these key numbers are better than expectatio ...

It has been about a month since the last earnings report for Incyte (INCY) . Shares have added about 1.8% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Incyte due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Incyte Q4 Earnings & Revenues Fall Short of Estimates ...

Incyte (INCY) announced new results from a mid-stage study evaluating the efficacy and safety of twice-daily Opzelura (ruxolitinib cream 1.5%) in adult patients with Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa (HS), a chronic, debilitating skin condition.The phase II study enrolled 69 adult patients (age ≥ 18 years) diagnosed with Hurley stage 1 or 2 HS who have a total abscess and inflammatory nodule (AN) count of 3 to ≤ 10, with no draining tunnels at screening and baseline visits.Resu ...

The allure of penny stocks is understandable. For literally just a few dollars, you can control hundreds, if not thousands, of shares. And if the stock moves just a nickel or dime higher, you can make a killing that sets you up for life.Unfortunately, that’s not the way most penny stocks work. They are just as likely (if not more) to be pump-and-dump scams as they are real companies trying to make their way. Often they won’t even have a product or service available. They are just a story, typically about wh ...